Immunoreactive EGF in human benign prostatic hyperplasia: relationships with androgen and estrogen receptors. 1992

C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
Istituto di V Clinica Medica, University of Rome La Sapienza, Italy.

Benign prostatic hyperplasia (BPH) is a sex steroid dependent disease. Estrogens and androgens can modulate in different mammalian tissues epidermal growth factor (EGF) production and/or secretion. In order to clarify the relationships between estrogen and androgen receptor concentrations and those of immunoreactive EGF (irEGF), we have evaluated these parameters in 14 human BPH samples, by means of a dextran-coated charcoal method and radioimmunoassay, respectively. Cytosolic steroid receptors did not seem to correlate with irEGF. A linear significative relationship was evident between nuclear androgen receptor (ARn) levels and endogenous irEGF but not between nuclear estrogen receptors and irEGF: in ARn negative BPH samples, irEGF levels were lower than in ARn positive ones. Therefore, it is possible that androgens act at prostatic tissue level, through their own receptors, by modulating EGF production and/or secretion.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011467 Prostate A gland in males that surrounds the neck of the URINARY BLADDER and the URETHRA. It secretes a substance that liquefies coagulated semen. It is situated in the pelvic cavity behind the lower part of the PUBIC SYMPHYSIS, above the deep layer of the triangular ligament, and rests upon the RECTUM. Prostates
D011470 Prostatic Hyperplasia Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both. Adenoma, Prostatic,Benign Prostatic Hyperplasia,Prostatic Adenoma,Prostatic Hyperplasia, Benign,Prostatic Hypertrophy,Prostatic Hypertrophy, Benign,Adenomas, Prostatic,Benign Prostatic Hyperplasias,Benign Prostatic Hypertrophy,Hyperplasia, Benign Prostatic,Hyperplasia, Prostatic,Hyperplasias, Benign Prostatic,Hypertrophies, Prostatic,Hypertrophy, Benign Prostatic,Hypertrophy, Prostatic,Prostatic Adenomas,Prostatic Hyperplasias, Benign,Prostatic Hypertrophies
D011863 Radioimmunoassay Classic quantitative assay for detection of antigen-antibody reactions using a radioactively labeled substance (radioligand) either directly or indirectly to measure the binding of the unlabeled substance to a specific antibody or other receptor system. Non-immunogenic substances (e.g., haptens) can be measured if coupled to larger carrier proteins (e.g., bovine gamma-globulin or human serum albumin) capable of inducing antibody formation. Radioimmunoassays
D011944 Receptors, Androgen Proteins, generally found in the CYTOPLASM, that specifically bind ANDROGENS and mediate their cellular actions. The complex of the androgen and receptor migrates to the CELL NUCLEUS where it induces transcription of specific segments of DNA. Androgen Receptors,5 alpha-Dihydrotestosterone Receptor,Androgen Receptor,Dihydrotestosterone Receptors,Receptor, Testosterone,Receptors, Androgens,Receptors, Dihydrotestosterone,Receptors, Stanolone,Stanolone Receptor,Testosterone Receptor,5 alpha Dihydrotestosterone Receptor,Androgens Receptors,Receptor, 5 alpha-Dihydrotestosterone,Receptor, Androgen,Receptor, Stanolone,Stanolone Receptors,alpha-Dihydrotestosterone Receptor, 5
D011960 Receptors, Estrogen Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important. Estrogen Receptor,Estrogen Receptors,Estrogen Nuclear Receptor,Estrogen Receptor Type I,Estrogen Receptor Type II,Estrogen Receptors Type I,Estrogen Receptors Type II,Receptor, Estrogen Nuclear,Receptors, Estrogen, Type I,Receptors, Estrogen, Type II,Nuclear Receptor, Estrogen,Receptor, Estrogen
D002467 Cell Nucleus Within a eukaryotic cell, a membrane-limited body which contains chromosomes and one or more nucleoli (CELL NUCLEOLUS). The nuclear membrane consists of a double unit-type membrane which is perforated by a number of pores; the outermost membrane is continuous with the ENDOPLASMIC RETICULUM. A cell may contain more than one nucleus. (From Singleton & Sainsbury, Dictionary of Microbiology and Molecular Biology, 2d ed) Cell Nuclei,Nuclei, Cell,Nucleus, Cell
D003600 Cytosol Intracellular fluid from the cytoplasm after removal of ORGANELLES and other insoluble cytoplasmic components. Cytosols
D004247 DNA A deoxyribonucleotide polymer that is the primary genetic material of all cells. Eukaryotic and prokaryotic organisms normally contain DNA in a double-stranded state, yet several important biological processes transiently involve single-stranded regions. DNA, which consists of a polysugar-phosphate backbone possessing projections of purines (adenine and guanine) and pyrimidines (thymine and cytosine), forms a double helix that is held together by hydrogen bonds between these purines and pyrimidines (adenine to thymine and guanine to cytosine). DNA, Double-Stranded,Deoxyribonucleic Acid,ds-DNA,DNA, Double Stranded,Double-Stranded DNA,ds DNA

Related Publications

C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
January 1993, Verhandlungen der Deutschen Gesellschaft fur Pathologie,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
January 2002, Zhonghua nan ke xue = National journal of andrology,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
July 2016, Bosnian journal of basic medical sciences,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
February 1983, Revista clinica espanola,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
July 1983, The Journal of urology,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
August 1999, Scandinavian journal of urology and nephrology,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
April 1984, Endocrinology,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
January 2009, Journal of andrology,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
March 2003, The Journal of clinical endocrinology and metabolism,
C Lubrano, and F Sciarra, and G Spera, and E Petrangeli, and V Toscano, and N Rombola, and F Palleschi, and E Palma, and F Di Silverio
November 1978, Research communications in chemical pathology and pharmacology,
Copied contents to your clipboard!